drugset / Trial / NCT00210366

Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma

NCT00210366

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The main objective of the trial is to assess the therapeutic activity of idarubicin as salvage treatment in patients with recurrent or progressive lymphoma in the central nervous system.

Timeline

Start
2004-11
Primary completion
2010-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Idarubicin Small molecule